ACE NanoMed Limited: Revolutionizing Cancer Treatment with Innovative Drug Solutions (Led by Prof Anna Chi Man TSANG and Prof Kwok Wai LO)
ACE NanoMed, a biomedical company specializing in the development of advanced therapies for cancers associated with the Epstein-Barr virus (EBV), is proud to announce its emergence as a significant player in the field of cancer research and treatment. Established in December 2022, ACE NanoMed has quickly gained recognition for its state-of-the-art approaches and has assembled a formidable team of experts to revolutionize cancer treatment strategies.
Led by two esteemed professors from the Chinese University of Hong Kong (CUHK), ACE NanoMed boasts a multidisciplinary team comprising experts from commercial fields, legal professionals, and medical practitioners. This diverse group of individuals brings together a wealth of knowledge and experience, positioning ACE NanoMed at the forefront of innovative drug development and commercialization.
One of the key focuses of ACE NanoMed is to develop groundbreaking treatments for cancers associated with the Epstein-Barr virus, including nasopharyngeal carcinoma, gastric cancer, Burkitt's lymphoma, and Hodgkin lymphoma. Traditional cancer treatments often come with debilitating side effects, impacting patients' quality of life. However, ACE NanoMed's drugs utilize innovative approaches such as aptamers and mRNA-based therapies, enabling precise targeting of cancer cells while sparing healthy cells. This breakthrough technology has the potential to significantly minimize side effects and improve treatment outcomes.
In recognition of its remarkable progress, ACE NanoMed has been selected to receive funding from the Technology Start-up Support Scheme for Universities (TSSSU), in alliance with an Angel Investor. This significant financial backing will propel ACE NanoMed's research and development efforts, bringing their invented drugs closer to clinical trials and eventual commercialization.
Furthermore, ACE NanoMed has been granted an offer from the Ideation Programme of the Hong Kong Science Park (HKSTP). The esteemed programme aims to foster and nurture technology-focused entrepreneurs, supporting them in transforming their visionary ideas into successful startups. This endorsement highlights ACE NanoMed's potential and underscores the company's dedication to realizing its mission of advancing cancer treatment solutions.
The recent success of ACE NanoMed extends beyond financial support and recognition. The company also achieved the esteemed accolade of First Runner Up in the CUHK Entrepreneurship Competition 2023. This achievement further exemplifies ACE NanoMed's commitment to innovation, entrepreneurship, and the pursuit of excellence.
"I am immensely proud of the remarkable progress ACE NanoMed has made in such a short span of time," said Professor Anna Tsang, Director of ACE NanoMed. "Our exceptional team of experts, coupled with our unwavering dedication to transforming cancer treatment, positions ACE NanoMed as a frontrunner in the field.” said Prof Kwok Wai Lo, Director of ACE NanoMed. We are excited to continue pushing boundaries, advancing our drug solutions, and ultimately making a significant impact on patients' lives."
ACE NanoMed is poised to redefine cancer treatment methodologies, leveraging cutting-edge research and development to create novel therapies that address the unique challenges posed by EBV-associated cancers. With a strong team, strategic partnerships, and a clear vision for the future, ACE NanoMed is poised to lead the charge in revolutionizing cancer treatment and improving patient outcomes.
